Clear all search history
Law & Crime
Disasters & Accidents
War & Conflict
Hospitality & Recreation
Neulasta articles over last 30 days
articles last 30 days
articles per day
Mentioned in this news
Fitch Affirms Amgen's IDR at 'BBB'; Outlook Remai...
... next three years, Amgen's aging product offering may see multi-source competition to
, Aranesp and Sensipar, that collectively represented 30.6% of total revenues for the latest...
Read more at
+ 14 more articles
Kinder Morgan Inc.
J.C. Penney Could See A 50% Increase
... their blockbuster drugs go off patent. One of those that they had is 32% of revenue, called
. This is a little different than a pill-type drug. This is a biologic. How do I describe...
Read more at Forbes
Latest from Twitter
Parts of this website powered by Open Calais, a toolkit for rich semantic metadata extraction.
Interceder is a topic search engine aggregating the latest news on any topic into a single window of information. This page has been automatically generated. To contact Interceder
Your privacy is important. Interceder does not collect and keep any personal information about visitors to the site. Interceder may use third-party advertising companies to serve ads. These companies may use information (not including your name, address, email address, or telephone number) about your visits to this and other websites in order to provide advertisements on this website, other websites, and other forms of media about goods and services of interest to you.